Lack of association between worsening renal function and mortality in heart failure patients treated with nesiritide

International Journal of Cardiology

Volumn 126, Issue 2, 2008, Pages 234-239

  Miller, Wayne L ^a   Kurien, Shaun ^a   Warfield, Karen T ^a   Wood, Christina M ^a   Jaffe, Allan S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Heart failure; Nesiritide; Outcomes; Renal function

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; NESIRITIDE; NITRATE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 42649089800     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.03.133     Document Type: Article

References (27)

1. de Bold A.J., Bruneau B.G., Kuroski J., et al. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 31 (1996) 7-18
2. Luchner A., Stevens T.L., Borgeson D.D., et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 274 (1998) H1684-H1689
3. Mukoyama M., Nakao K., Saito Y., et al. Human brain natriuretic peptide, a novel cardiac hormone. Lancet 335 (1990) 801-802
4. Mukoyama M., Nakao K., Saito Y., et al. Increased human brain natriuretic peptide in congestive heart failure. N Engl J Med 323 (1990) 757-758
5. Anand I.S., Fisher L.D., Chiang Y.-T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
6. Yamamoto K., Burnett Jr. J.C., and Redfield M.M. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol 273 5,pt 2 (1997) H2406-H2414
7. Koglin J., Pehlivanli S., Schwaiblmair M., et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38 (2001) 1934-1941
8. Colucci W.S., et al., for the Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343 (2000) 246-253
9. Young J.B., and for the Publications Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. A randomized controlled trial. JAMA 287 (2002) 1531-1540
10. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
11. Sackner-Bernstein J.D., Kowalski M., Fox M., et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure. JAMA 293 (2005) 1900-2005
12. Wang D.J., Dowling T.C., Meadows D., et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110 (2004) 1620-1625
13. Butler J., et al., on behalf of the VMAC study investigators. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant 19 (2004) 391-399
14. Abraham W.T., Lowes B.D., Ferguson D.A., et al. Systemic hemodynamic, neurohormonal, and renal effects of steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 4 (1998) 37-44
15. McCullough P.A., Joseph K., and Mathur V.S. Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. Rev Cardiovasc Med 5 (2004) 16-25
16. Yoshimura M., Yasue H., Morita E., et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84 (1991) 1581-1588
17. Miller W.L., Burnett Jr. J.C., Hartman K.A., et al. Lower rather than higher levels of B-type natriuretic peptides predict short-term mortality in end-stage heart failure patients treated with nesiritide. Am J Cardiol 96 (2005) 837-841
18. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
19. Riter H.G., Refdield M.M., Burnett J.C., et al. Non-hypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 46 (2006) 2334-2335
20. Gottlieb S.S., Abraham W., Butler J., et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 8 (2002) 136-141
21. Forman D.E., Butler J., Wang Y., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43 (2004) 61-67
22. Butler J., Forman D.E., Abraham W.T., et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 147 (2004) 331-338
23. Ympa Y.P., Sakr Y., Reinhart K., et al. Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Cardiol 118 (2005) 827-832
24. Fonarow G.C., et al., for the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acute decompensated heart failure. Classification and regression tree analysis. JAMA 293 (2005) 572-580
25. Packer M., Fowler M.B., Roecker E.B., et al. Effect of Carvedilol on the morbidity of patients with severe chronic heart failure (COPERNICUS). Circulation 106 (2002) 2194-2199
26. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES). N Engl J Med 341 (1999) 709-717
27. Swedberg K., and and the CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316 (1987) 1429-1435